Media coverage
92
Media coverage
Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Morningstar.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959708377&p=1gw&v=1&x=qd0TRWtU72arh3X8ymSUOg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet PR Newswire Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959755524&p=1gw&v=1&x=wBtlRDXC_OrkfffRUtNuaA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet BioSpace Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48960991748&p=1gw&v=1&x=4xqvtNc_v_wEbrhbaKuCiw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of.. Media name/outlet ADVFN UK Country/Territory United Kingdom Date 11/10/22 URL ct.moreover.com/?a=48959676828&p=1gw&v=1&x=ASWlc1HVkfNNfkqgpOvnuA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet ADVFN UK Country/Territory United Kingdom Date 11/10/22 URL ct.moreover.com/?a=48959686485&p=1gw&v=1&x=VNkbaOwOH8xeaMDJtm4iDg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Yahoo! Finance Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959734969&p=1gw&v=1&x=vSck8GifIyWY9JjSRXo7Bw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet MarketScreener.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959673782&p=1gw&v=1&x=muoXSsaPlHBufhUUJcER5g Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet APNews.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959862651&p=1gw&v=1&x=btCU7cl0n6y-tSTtXZOq0w Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Market Newsdesk Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959718075&p=1gw&v=1&x=l9vYq6aVzZMqey7lHzSKfQ Persons Mirna Chehade Title Dupixent(R) (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet TD Ameritrade Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959680548&p=1gw&v=1&x=-wxYuCo9BvSgONrB9Y_NPQ Persons Mirna Chehade Title Dupixent(TM) (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Stockwatch Country/Territory Canada Date 11/10/22 URL ct.moreover.com/?a=48959680967&p=1gw&v=1&x=gibJaTECZCL-f2PsbJ5w0Q Persons Mirna Chehade Title Dupixent (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Chase Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959684375&p=1gw&v=1&x=2dVrQz_aaGqCsv7xRW07Fw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet TickerTech.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959684685&p=1gw&v=1&x=L-67_IS3QfvoNkMSS5-0kw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Markets Business Insider Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959694730&p=1gw&v=1&x=vEIzyMQ8jWtOPamRoLkoYg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet ProfitQuotes.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959699711&p=1gw&v=1&x=sTTHouP2EsV4e-VLzUSBSA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Spoke.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959742508&p=1gw&v=1&x=aIIxLg8J7sTRQZ2TUKSDrw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Crwe World Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959757069&p=1gw&v=1&x=ZCWUALq9_lWbZGj4ttYiJA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WTVM Country/Territory Georgia Date 11/10/22 URL ct.moreover.com/?a=48959680092&p=1gw&v=1&x=W_zcdikj14YddRqNv-XmyQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Upper Michigans Source Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959680068&p=1gw&v=1&x=Rj5NhlP_GbioXIAsaAMmVA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet NBC12 Online Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959677579&p=1gw&v=1&x=CSYw9WeB3sv7KPGjEDMNFA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WSFA Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959681169&p=1gw&v=1&x=UAFv2vL9twzIJDDijuxq1A Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet NewsChannel 10 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959681170&p=1gw&v=1&x=tJ0gHroq3bGiXEh1yycLEA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WVLT Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959681175&p=1gw&v=1&x=jFhE3Z9m_lc2VjL0XiuJBg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KOLO TV Reno Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959681713&p=1gw&v=1&x=8OtrNklFFac9CI1nAbnB9Q Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet NBCNebraskaScottsbluff.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959681799&p=1gw&v=1&x=pDLzNYZuy4BeGdP3yHBipw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KKTV.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959683143&p=1gw&v=1&x=_aM73uYUAOSN0H7YUH7agw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Fox 19 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959683956&p=1gw&v=1&x=u-_dzMKqtPydOAKvHTLIMQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WLOX Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959688893&p=1gw&v=1&x=-YCHmARheHini54fGXkc3A Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Hawaii News Now Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959694940&p=1gw&v=1&x=dgUqxOBIs6TURm2KoLAmsw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KBTX.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959691573&p=1gw&v=1&x=ErmVjJOk0boC1lUUJOakIw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WSAZ Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959691544&p=1gw&v=1&x=pXBWrmzUW8o375xBPgDWEQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KCRG.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959697257&p=1gw&v=1&x=ypnQqAvEMmjXviJynxVFyA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WALB 10 Country/Territory Georgia Date 11/10/22 URL ct.moreover.com/?a=48959698845&p=1gw&v=1&x=eEbsOTmptDwlfp94OwJ9EA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WBKO Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959701416&p=1gw&v=1&x=5mTkCC-hcQzidHe5P56rbw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KWTX Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959703705&p=1gw&v=1&x=4lcsoHISqWqSJ7X-XCbOew Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KCBD Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959703865&p=1gw&v=1&x=au6ltRQf160Ya8fcyaIV0A Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WKYT Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959709317&p=1gw&v=1&x=TUpLZ6alYqb-AuYEEyRyFA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WBRC Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959709629&p=1gw&v=1&x=TqQ8eoEVz2XIGF1aCQdeWQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Webcenter 11 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959712046&p=1gw&v=1&x=NwRHo5YYbtCSI0pHBVT2tA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KYTV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959714920&p=1gw&v=1&x=Al0rCOBbccPQ0dze5FG8mg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Wave 3 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959726590&p=1gw&v=1&x=VgmPSTxTBB7eRRNSGa0XEQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet VB Profiles Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959699503&p=1gw&v=1&x=kptaEdSploXHVUUjcVs6jA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Elizabethton.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959705002&p=1gw&v=1&x=1SNsPH30Wa3e8myHpN4oAQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Smithfield Times Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959708776&p=1gw&v=1&x=wrSp2ItYry7MjAJlyqIbuQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Salisbury Post Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959711470&p=1gw&v=1&x=GRioDX9jMsGgaUCeMXt4mw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic... Media name/outlet Charlotte Gazette Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959713296&p=1gw&v=1&x=UCaxZ1cCaJmxNRXvZSGK-Q Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Harlan Daily Enterprise Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959714256&p=1gw&v=1&x=MZOQt5oAH_Pp-GgnQLbzPw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Suffolk News Herald Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959714456&p=1gw&v=1&x=ay_zgiwaYSkjb8J1r4cbGA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Port Arthur News Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959721028&p=1gw&v=1&x=grFOXGBY6Qp1ByKVt4h88w Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet LaGrange Daily News Country/Territory Georgia Date 11/10/22 URL ct.moreover.com/?a=48959722315&p=1gw&v=1&x=HmBfeiWK3vJiXDmaFEjRNg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Winchester Sun Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959726662&p=1gw&v=1&x=VQ1PmYYJs5hlkCHziQkKAg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Jessamine Journal Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959731048&p=1gw&v=1&x=KuNkm-2R6-zDnjXO9qaGjw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WANE-TV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959734245&p=1gw&v=1&x=CrR1qy0oK6WzRAL31QifjA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959738083&p=1gw&v=1&x=9NsvRRPBThFOJOvGInvHOA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet CW39 NewsFix Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959738529&p=1gw&v=1&x=OG0n04KokJkzrK9-jtnqyQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WATE Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959739200&p=1gw&v=1&x=dLH6TcmIUswrjBOPeF879Q Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KTLA Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959739927&p=1gw&v=1&x=SMczVShMBaO6bDDSshmGjA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet FOX5 San Diego Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959740627&p=1gw&v=1&x=Ezxs44t3pbvME6EUKleEtw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WWLP.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959742516&p=1gw&v=1&x=tGUc5o-P0n0zoiD61EbYGQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WIVB Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959742741&p=1gw&v=1&x=lkLviA2LE-XhpiRgdf0SNg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet CBS17.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959745857&p=1gw&v=1&x=hXdHPuK7XLnm2LHXQArGGg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Everything Lubbock Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959748466&p=1gw&v=1&x=wHSnf2-SRNLCJ8jJm59pzw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WTen.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959761529&p=1gw&v=1&x=nXcRThLPZBJ3xHO-A1jwuw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet FOX8 WGHP Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959762804&p=1gw&v=1&x=SZCW2iMolVB01pyaKOAh3w Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WKBN 27 First News Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959763533&p=1gw&v=1&x=BV3JdtBFnxaMlYfIVbf33w Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Wood TV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959766585&p=1gw&v=1&x=-s0hyU4kC7VO5Sz1Z784cQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WGN-TV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959770373&p=1gw&v=1&x=8-Q5uukL8CLKNdNTz_5Q1Q Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WKRN Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959780114&p=1gw&v=1&x=FScfPYmbcRO1L8T0JywExQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet ABC 27 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959780512&p=1gw&v=1&x=dgxFgmNVuE-eJIToD2EVzw Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet FOX 31 News KDVR Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959797201&p=1gw&v=1&x=k3KNyGYzLBzv8JWgEpvUOA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet YOUR BASIN Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959797469&p=1gw&v=1&x=u85_Rr5jpKMLwmLGT3wcEg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Siouxland Matters Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959799393&p=1gw&v=1&x=UFR3y30Ha9NKr5ChkuVRtQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KXAN Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959801106&p=1gw&v=1&x=8eVflH1-AsdaAobzLH8wMQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Fox 2 Now Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959806563&p=1gw&v=1&x=uC6UbJU24lJvw6gNlm6VEQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WGNO Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959809055&p=1gw&v=1&x=D4cxMRnA_y61qY5xAFxltg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet FOX 59 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959809139&p=1gw&v=1&x=AhZ5WSSzoxcZ7jUEnQBgng Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KOIN Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959819960&p=1gw&v=1&x=5-TFQoAbbSc3EoplHB4DxA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WJHL.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959837257&p=1gw&v=1&x=AU6bvkEJMkiFBYBxa-SM_A Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet PIX11 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959838976&p=1gw&v=1&x=wFYeEfrxGj8Nkcx2fF4eJA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WTWO Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959851316&p=1gw&v=1&x=BV5kty8DtlapGnCARwGWLA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WRIC TV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959860387&p=1gw&v=1&x=EjkWsjqWHlAZOfxxMwzLlA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet MyPanhandle.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959860926&p=1gw&v=1&x=koFtiPhAfzxyR0nP5GvFYA Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet News Channel 8 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959861019&p=1gw&v=1&x=KQC9cQfH1SJDFjvDgQRTjQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Fox 16 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959863533&p=1gw&v=1&x=XyblOudT3t2ae1n3rF5lkg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet WREG Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959865624&p=1gw&v=1&x=OMC9QGcmE17VCBGzqjrb5Q Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KRON4 Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959865604&p=1gw&v=1&x=cXDX1WY5nU-ov5IatTm0og Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet 8 News Now Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959871131&p=1gw&v=1&x=5dwc1JBtgdveRkqVP23oag Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet KFOR.com Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959884235&p=1gw&v=1&x=LlbVyryb5xQT0vtBcD3_CQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet NBC4 Columbus Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48959889711&p=1gw&v=1&x=mZB45YZNrwfnaj-55xBYBg Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48960258162&p=1gw&v=1&x=HCQNbiFnTM1PLox-dn5DLQ Persons Mirna Chehade Title Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old Media name/outlet Regeneron Country/Territory United States Date 11/10/22 URL ct.moreover.com/?a=48961202948&p=1gw&v=1&x=-_a9EAcaQmKVbiOsATHe-A Persons Mirna Chehade Title Dupixent® (Dupilumab) Late-Breaking Phase 3 Data Presented At UEG Week 2022 Showed Significant Histological Remission Of Eosinophilic Esophagitis (Eoe) In Children 1 To 11 Years Old' Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 11/10/22 URL ct.moreover.com/?a=48960075754&p=1gw&v=1&x=aFg1WVJ5mANzlGj7fEFKdw Persons Mirna Chehade